<DOC>
	<DOCNO>NCT02280434</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , pharmacokinetics pharmacodynamics CBP-307 follow oral single multiple escalate dose administration healthy subject .</brief_summary>
	<brief_title>Phase 1 Study Accessing Safety Tolerability CBP-307</brief_title>
	<detailed_description>This study evaluate safety , tolerability , pharmacokinetics pharmacodynamics CBP-307 follow oral single multiple escalate dose administration healthy subject . The study two part : Part 1 ass 5 dose level drug single dosing ; Part 2 evaluate 3 dose level 28-day repeat dosing . The effect food also evaluate single dosing study .</detailed_description>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<criteria>Informed consent must obtain write subject enrollment study Healthy male subject age 18 55 year , inclusive Body mass index ( BMI ) 19 30 kg/m2 , inclusive No clinically significant finding medical history physical examination , especially regard liver gastrointestinal system No clinically significant laboratory value urinalysis , unless investigator considers abnormality clinically irrelevant Normal ECG , blood pressure , heart rate , unless investigator considers abnormality clinically irrelevant Resting heart rate ≥ 55 bpm Family history premature CHD ( Coronary Heart Disease ) Any condition require regular use medication Exposure prescription medication drug know interfere metabolism drug within 30 day prior screen Exposure medication , include overthe counter medication , herbal remedy vitamins 14 day prior randomization ( except paracetamol ( see Section 5.2 Prior concomitant treatment ) Participation another study investigational drug 2 month precede study Treatment previous 3 month drug know well define potential toxicity major organ Positive urine cotinine result screen Be exclusion period previous study investigational drug Symptoms clinically significant illness 3 month study Presence sequelae gastrointestinal , liver kidney disease , condition know interfere absorption , distribution , metabolism , excretion drug Chronic constipation diarrhea , irritable bowel syndrome , inflammatory bowel disease Hemorrhoids anal disease regular recent presence blood feces History significant allergic disease ( e.g . medication ) acute phase allergic rhinitis previous 2 week randomization food allergy Blood plasma donation 500 ml previous 2 month randomization and/or 50 ml 2 week prior screen Subjects risk tuberculosis ( TB ) , specifically subject : Current clinical , radiographic laboratory evidence active TB ; history active TB unless documentation prior antiTB treatment appropriate duration type ; latent TB successfully treat ; positive quantiFERON® test screening within 6 month prior Day 1 Known positive test HIV Known positive test hepatitis B ( antigens HBs , antibody HBc ) C , unless cause immunization History shingle recurrent episode HSV1 HSV2 infection Current evidence drug abuse history drug abuse within one year randomization History alcohol abuse active alcoholism define Appendix A Definition alcohol abuse Mental condition render subject incapable understand nature , scope , possible consequence study Adults guardianship people restriction freedom administrative legal decision Unlikely comply clinical study protocol ; e.g . uncooperative attitude , inability return followup visit , improbability complete study Subject investigator subinvestigator , research assistant , pharmacist , study coordinator , staff relative thereof directly involve conduct protocol . Systolic blood pressure le 95 mmHg great 140 mmHg , diastolic blood pressure less equal 50 mmHg great equal 95 mmHg . Subjects rest heart rate le 55 beat per minute great 90 beat per minute .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>